Replies to post #153098 on Biotech Values

[bladerunner1717]

Caravon,

Are you implying that there were an unusually high number of C-Met low patients in the Tivantinib trial?

As I recall--it may have been another poster--you felt that ARQL had given up much too early on lung cancer. Do you still feel that way?


Bladerunner